ABI, Asuragen to Collaborate with Critical Path Institute on Drug Toxicity Biomarkers | GenomeWeb
NEW YORK (GenomeWeb News) – Applied Biosystems and Asuragen are collaborating with the Critical Path Institute’s Predictive Safety Testing Consortium to develop a predictive gene signature panel that pharmaceutical companies can use to screen pre-clinical therapeutics for toxicity, ABI announced today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.